Human (autologous) bone marrow-derived mesenchymal stem cell 1 set

Open tender

Japanese title: ヒト(自己)骨髄由来間葉系幹細胞1セット

Medical
About this page
This page is based on the official tender notice and presents information processed, translated, and edited by JBID.

Overview

Tottori University is procuring one set of human (autologous) bone marrow-derived mesenchymal stem cells. Delivery is scheduled between September 14, 2026 and March 31, 2027 to the Department of Hospital Pharmacy at Tottori University Hospital. Participation requires specific qualifications including pharmaceutical sales licenses and compliance with university regulations.

Key Details

  • Source: Kanpo
  • Notice type: Open tender
  • Publication date: July 16, 2026
  • Procuring entity: Tasuku Harada, President, Tottori University
  • Submission deadline: September 7, 2026, 17:00 JST
  • Bid opening: September 14, 2026, 10:00 JST, location: see the official notice
  • Award method: Lowest-price award
  • Eligibility (from notice): All-ministry unified qualification, 'goods sales', grade A–C, Chugoku region – verify in the tender documents
  • Status: Expired
  • Technology relevance: Possible
  • Business-action likelihood: Medium – Open competitive bidding with specific qualification requirements and pharmaceutical licensing; local regulatory compliance and certification needed.

Official Notice

Official Source

Kanpo, Japan's official government gazette, in which legally required public procurement notices are formally published.

  • Source: Kanpo, Government Procurement Notice Edition
  • Official category: 入札公告 / Open competitive tender notice
  • Publication date: July 16, 2026
  • Publication: Kanpo, pages 31-32

Full English Translation

The following English translation was prepared from the original Japanese notice published in Kanpo. Where an official English summary appears in the Kanpo publication, it was used only for verification; the translation below is based on the Japanese source text.

Tender Notice:
The following is subject to open competitive bidding. Date: July 16, 2026. Procuring entity: Tasuku Harada, President, National University Corporation Tottori University. Procurement agency number: 415. Location number: 31. Item classification number:

4. Procurement subject and quantity:
Human (autologous) bone marrow-derived mesenchymal stem cell 1 set. Characteristics of procurement subject: As per the bidding documents. Delivery period: From September 14, 2026 to March 31, 2027. Delivery location: Department of Hospital Pharmacy, Tottori University Hospital. Bidding method: The successful bid price will be the bid amount plus 10% of that amount; bidders must state 100/110 of the estimated contract amount regardless of tax status. Eligibility: Bidders must not fall under Articles 5 and 6 of Tottori University's contract handling regulations. Minors or persons under guardianship with necessary consent may be eligible under special reasons. Bidders must hold A, B, or C grade qualification for 'sales of goods' in the Chugoku region for fiscal 2026 under national or university qualification systems. Bidders must prove they hold a general pharmaceutical sales license under the Pharmaceutical and Medical Device Act. Bidders must prove capability to deliver the goods at the date and place designated by the university president. Bidders must not be under transaction suspension by the university president. Submission location and inquiries: Tottori University Yonago Campus, Accounting and Procurement Section, Hospital Logistics, Sawada Yoshinori, phone 0859-38-7068. Bidding documents available from the date of this notice at the above location. Bid submission deadline: September 7, 2026, 17:00. Bid opening: September 14, 2026, 10:00, Tottori University Hospital TV conference room. Contract language and currency: Japanese and Japanese yen. Bid and contract guarantees are exempted. Bidders must submit sealed bids with documents proving ability to deliver the goods by the deadline. Bidders must respond to explanations requested by the university president before bid opening. Invalid bids include those from ineligible bidders or those failing obligations. Contract document required. Successful bidder: The lowest valid bid within the price limit judged capable by the university president. No negotiation in procedure. Further details in bidding documents. If environmental conditions are specified in bidding documents, bidders should understand them fully before bidding.
Show original Japanese notice

The full Japanese notice text is temporarily hidden on this page due to a text-extraction defect. The official notice is available via the Kanpo source link on this page.

Business Signal

Business Relevance

May interest companies providing advanced biomedical products or stem cell therapies, especially those capable of supplying human autologous mesenchymal stem cells.

Participation fit

Participation is expected to require appropriate Japanese government procurement eligibility, or cooperation with a suitable Japanese partner holding the required qualification. The eligibility requirements have not been fully reviewed and should be verified against the official tender documents.

This page is based on the official Kanpo tender notice, with translation and a preliminary business assessment by I.J. Do. The official Japanese notice and tender documents are binding.

JBid is a beta technology-procurement intelligence service by I.J. Do.

Back to daily list